Gonlugur Ugur, Gonlugur Tanseli Efeoglu
Department of Chest Diseases, Canakkale Onsekiz Mart University, Canakkale, Turkey.
Arch Environ Occup Health. 2010 Apr-Jun;65(2):65-9. doi: 10.1080/19338240903390271.
The aim of this study was to investigate the effects of various clinical, laboratory characteristics, and therapeutic modalities on the survival of patients with malignant pleural mesothelioma. One hundred consecutive patients with a pathologically proven diagnosis of malignant pleural mesothelioma treated between 1993 and 2005 were included in the study. Using a Cox proportional hazard model, comorbidity, weight loss, breathlessness, and performance status were identified as independent prognostic factors. Comorbidity had interestingly favorable effect on the survival. Treated patients with chemotherapy had significantly longer survival than those treated with best supportive care. However, it was necessary to complete at least 6 cycles for a survival benefit. In conclusions, comorbidity information should be recorded in the recent prognostic studies. The drugs used for the comorbidity may improve survival.
本研究的目的是探讨各种临床、实验室特征及治疗方式对恶性胸膜间皮瘤患者生存的影响。本研究纳入了1993年至2005年间连续收治的100例经病理证实诊断为恶性胸膜间皮瘤的患者。采用Cox比例风险模型，确定合并症、体重减轻、呼吸困难和体能状态为独立的预后因素。有趣的是，合并症对生存有有利影响。接受化疗的患者生存时间明显长于接受最佳支持治疗的患者。然而，为了获得生存获益，至少需要完成6个周期的化疗。总之，在近期的预后研究中应记录合并症信息。用于治疗合并症的药物可能会提高生存率。
